Transient and fully reversible changes in laboratory parameters and modifications of the cytokine profile during blinatumomab treatment in children with relapsed or refractory B-cell acute lymphoblastic leukemia
- Franco Locatelli
- , Ana Markovic
- , Matthias Klinger
- , Ting Zeng
- , Gerhard Zugmaier
- Amgen Incorporated
Risultato della ricerca: Contributo in rivista › Abstract di Conferenza